SaNOtize Leaders (Twitter pic)
SaNOtize Research & Development Corp., an Israel startup that is focused on new anti-infective therapeutics, raised $34 million in a Series B funding round co-led by Horizons Ventures and OurCrowd, with participation from ABC International. The lead treatment in the company’s pipeline is its nitric oxide nasal spray (NONS™), shown in clinical studies to treat and prevent COVID-19 infection.
Founded in 2017 by Dr. Regev and Chief Scientific Officer and Co-Founder, Chris Miller, Ph.D., SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete’s foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others.
With antibiotic resistance increasing in the world, SaNOtize’s platform technology can help fight resistance and bring a new innovating solution to fight infections.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The CDC explains that antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to CDC’s 2019 Antibiotic Resistance (AR) Threats Report. When Clostridioides difficile—a bacterium that is not typically resistant but can cause deadly diarrhea and is associated with antimicrobial use—is added to these, the U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths.
Antimicrobial resistance has the potential to affect people at any stage of life, as well as the healthcare, veterinary, and agriculture industries, making it one of the world’s most urgent public health problems.
In SaNOtize’s clinical studies, NONS has been shown to rapidly reduce viral load in those with COVID-19 and decrease the risk of infection after known exposure. In a recent Phase 3 study, NONS shortened the time to negative PCR and demonstrated a reduction in SARS-CoV-2 viral burden in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively. Similar results were found in an earlier Phase 2 trial (95% reduction of viral RNA in 24 hours and 99% in 72 hours). As a preventive measure, those using NONS after a high-risk close contact exposure to COVID-19 were 75% less likely to become infected when compared to a control group, shown in an observational study.
“We are thrilled to embark on these new partnerships, as they empower SaNOtize to accelerate its research program in various therapeutic fields and expand our Phase 3 NONS COVID-19 trial to additional countries,” said Gilly Regev, PhD, SaNOtize Co-Founder and CEO. “Our clinical and observational studies found NONS to be safe and effective at both treating and preventing COVID-19, even amid delta and omicron surges. We look forward to expanding our clinical research and working toward regulatory approval in the United States and Canada.”
